Vesugen

Vesugen's proposed mechanism follows the three-stage Khavinson short-peptide framework. At the pharmacokinetic level, oral dosing is claimed to produce sufficient intact peptide absorption to deliver bioactive quantities to target tissues. Radiolabeled studies from Khavinson's group in rodent models have reported that short peptides of this class reach vascular and endothelial tissue within hours of oral dosing, with nuclear accumulation at concentrations thought to support direct chromatin interaction (Khavinson, 2011). The extent to which these rodent findings translate to meaningful bioavailability at human oral doses of 2 to 4 mg peptide is not independently established.

At the cellular level, Vesugen is claimed to act on three vascular cell types.

On endothelial cells, Vesugen is claimed to upregulate endothelial nitric oxide synthase (eNOS) expression and activity, increasing basal and shear-induced nitric oxide production. Nitric oxide is the central endothelial relaxation factor; its bioavailability is reduced in aging, hypertension, diabetes, and smoking. If Vesugen genuinely increases eNOS-dependent NO signaling, the downstream effects would include vessel relaxation, modestly improved flow-mediated dilation, reduced platelet aggregation, and reduced leukocyte adhesion to endothelial surface. These are the same biological levers that statins, ACE inhibitors, ARBs, and metformin engage through different mechanisms, so any Vesugen effect in this domain is additive with established therapy rather than replacing it.

On vascular smooth muscle cells, Vesugen is claimed to modulate the proliferative and contractile balance toward a quiescent healthy phenotype, opposing the migratory-synthetic phenotype characteristic of atherogenic vessel wall remodeling. The molecular detail supporting this claim in independent Western literature is limited. If such an effect were real and reproducible, it would align with the known benefit of long-term statin therapy on plaque stability.

On progenitor-like vascular cells (including circulating endothelial progenitor cells mobilized from bone marrow), Vesugen is claimed to support mobilization and homing to sites of endothelial injury. This is a more speculative claim, and Western evidence for small-molecule modulation of endothelial progenitor cells is heavily disputed.

At the molecular level, the sequence-selective DNA binding model proposes that Vesugen's tripeptide (H-Lys-Glu-Asp) makes specific contacts with promoter regions of vascular-specific genes. The positive and negative charges of the lysine, glutamate, and aspartate side chains are proposed to support electrostatic interactions with the DNA backbone, while the side chain arrangement creates geometric complementarity with specific nucleotide sequences in the major groove. This model is plausible in cell-free systems. Its operation at physiologically relevant concentrations in intact vascular tissue cells has not been broadly replicated.

Beyond the core Khavinson framework, short KED and related peptides have been studied for their effects on specific molecular targets that are relevant to vascular biology:

Nitric oxide synthase pathway: Vesugen's proposed upregulation of eNOS would raise baseline NO production. ADMA (asymmetric dimethylarginine), an endogenous eNOS inhibitor elevated in cardiovascular disease, might be modulated downstream. No dedicated human ADMA dataset exists for Vesugen.

Inflammatory gene expression: Vesugen is claimed to suppress NF-kB-driven pro-inflammatory gene expression in endothelial cells, reducing cytokine and adhesion molecule expression. If real, this would reduce leukocyte recruitment to vessel wall, a key step in atherogenesis. Again, the specific evidence for Vesugen modulation of this pathway in humans is not well characterized.

VEGF pathway: Vascular endothelial growth factor (VEGF) signaling is central to neovascularization and endothelial repair. Some Khavinson-group reports suggest that short vascular peptides modulate VEGF expression in aged vascular tissue, supporting a partial restoration of repair capacity. The quantitative evidence is thin.

Telomere and senescence pathways: Endothelial cell senescence contributes to vascular aging. Epitalon, the flagship Khavinson pineal peptide, has attracted attention for reported effects on telomerase expression. Vesugen is sometimes claimed to similarly support telomerase activity in vascular cells. These claims cross over between Khavinson papers and are not supported by large Western replication studies.

Practically, what should a reader take from the mechanism story? The proposed mechanism is coherent with what we know about endothelial biology and vascular aging. It touches the same pathways that statins, ACE inhibitors, ARBs, SGLT2 inhibitors, GLP-1 agonists, and lifestyle interventions engage. If Vesugen produces a real but modest effect on any of these pathways, its contribution stacks additively with established therapy rather than replacing it. If Vesugen does not produce a meaningful effect in humans — a possibility that cannot be ruled out given the evidence gap — then the placebo and Hawthorne components of starting a new supplement routine may explain most reported benefit. The honest framing is that users should expect small or unmeasurable changes, should not discontinue evidence-based cardiovascular medications to rely on Vesugen, and should evaluate their response based on objective markers (blood pressure, lipids, HbA1c, HRV, flow-mediated dilation if available) rather than subjective impressions alone.

Vesugen is a short synthetic peptide developed within Vladimir Khavinson's laboratory at the Saint Petersburg Institute of Bioregulation and Gerontology and marketed in Russia as an oral capsule for vascular and endothelial system support. The reported sequence is a tripeptide, H-Lys-Glu-Asp-OH (KED), though some sources list it with a C-terminal amide. Within the Khavinson short-peptide bioregulator catalog — Epitalon, Thymogen, Pinealon, Vilon, Livagen, Bronchogen, Cardiogen, Cartalax, Chonluten, Ovagen, Testagen, and Prostamax — Vesugen occupies the vascular tissue niche. Cardiogen is the companion cardiac peptide; Vesugen is marketed specifically for the vessel wall rather than the myocardium.

Like the rest of the Khavinson capsule line, commercial Vesugen is a 20 milligram nominal capsule containing approximately 2 to 4 milligrams of synthetic peptide dispersed in milk-protein and starch excipients. The 20 mg on the bottle refers to total powder weight, not peptide dose. This matters because users reading vendor sites sometimes assume they are getting a much larger peptide quantity than is actually present.

Vesugen is sold as an over-the-counter supplement in Russia and Eastern Europe and as a research compound in other markets. It is not a registered pharmaceutical in the United States, the European Union, the United Kingdom, Canada, or Australia. It is not FDA-approved for any indication. It has not undergone phase 3 Western randomized controlled trials. All human clinical evidence for Vesugen is from small single-center Russian-language observations and reviews from Khavinson's group and affiliated collaborators, with limited independent replication. Readers evaluating Vesugen for their own cardiovascular health are comparing a niche Russian bioregulator to mainstream cardiology pharmacology — statins, PCSK9 inhibitors, ezetimibe, antihypertensives, antiplatelet agents, SGLT2 inhibitors, and GLP-1 agonists — where the evidence gap is enormous.

BodyHackGuide treats Vesugen honestly rather than promotionally. If a reader is researching vascular bioregulators, the goal of this page is to explain what Vesugen is, what the Khavinson framework claims, where the evidence is thin, how it would theoretically fit into a serious cardiovascular prevention plan, what safer and better-evidenced alternatives exist, and which contraindications and interactions matter. The framing throughout is that Vesugen is at best a low-priority adjunct in a well-constructed vascular health plan, and at worst an unnecessary purchase that displaces attention from the evidence-based interventions that actually move cardiovascular outcomes. A reader worried about vascular aging, endothelial dysfunction, hypertension, hyperlipidemia, atherosclerosis, stroke risk, or peripheral arterial disease should be working with a cardiologist or internist on statins, antihypertensives, antiplatelets, and lifestyle — not relying on a Russian tripeptide.

The Khavinson framework for Vesugen follows the same three-stage mechanistic story that applies to the whole short-peptide line. Stage one is absorption from the gut and passive membrane crossing into target tissue cells. Stage two is passive nuclear import, with short peptides entering nuclei and reaching chromatin. Stage three is sequence-selective binding to DNA regulatory regions associated with vascular and endothelial gene programs. In Vesugen's case, the target tissue is claimed to be vascular smooth muscle and endothelium, with effects on endothelial nitric oxide synthase (eNOS), endothelial growth factors, pro- and anti-inflammatory gene regulation, and the chromatin state of aging endothelial cells. The claim is that cycled oral dosing can partially reset the endothelial transcriptional program back toward a younger pattern, improving nitric oxide bioavailability, vessel relaxation, and resistance to atherogenic lipid deposition.

That framework is elegant but not robustly validated outside Khavinson's laboratory. The biochemical basis for short-peptide tissue selectivity remains contested in mainstream molecular biology. The pharmacokinetic claim — that orally delivered tripeptides survive gastric proteolysis, cross the gut wall intact, and reach vascular tissue nuclei at concentrations relevant to gene regulation — is not independently established at the quantitative level required to support the clinical claims. A reader should understand that the mechanism-of-action story is a theoretical model rather than a settled body of biochemistry.

The main demographic buying Vesugen is men and women in their forties through sixties who are worried about vascular aging. Typical concerns include: modestly elevated blood pressure, borderline lipid panels, family history of stroke or myocardial infarction, peripheral cool extremities, varicose veins or spider veins, concerns about erectile or sexual vascular function, mild endothelial dysfunction markers, concerns about dementia-vascular pathology overlap, and generalized "longevity" interests. Each of those concerns has an evidence-based workup and treatment pathway that vastly outstrips what Vesugen can offer. A reader with one or more of those concerns should be working through that pathway — not treating a Russian capsule as a shortcut.

Vesugen is most commonly used in a 10-days-on cycle followed by a 60 to 90 day washout, per the Khavinson cycling convention. Each dose is 1 or 2 capsules on an empty morning stomach. Cycles are typically repeated two to four times per year, often paired with Cardiogen (for those with both cardiac and vascular concerns), Epitalon (for generalized longevity framing), Pinealon (for cognitive-vascular overlap), or Thymogen (immune support). Reconstitution is not required for the oral capsule form. Injectable Vesugen is a research-chemical formulation rather than the commercial product and is not recommended for users without research-chemical experience and clinical oversight.

Safety observation in the published Khavinson work has been consistently reassuring at the oral doses used, but the trial base is small and short. This page treats "well tolerated" as a provisional claim rather than a conclusion. The theoretical safety concerns specific to Vesugen include drug interactions with antihypertensives and antiplatelets (where additive effects are possible but uncharacterized), interactions with statins (where no direct interaction is known but monitoring is reasonable), and interactions with anticoagulants (where peptide effects on coagulation and platelet function are not characterized in published data). A reader on these classes of medications should consult their cardiologist before starting Vesugen — not for regulatory reasons but for coherent integration of any observed effects with their existing therapy.

The honest positioning on this page: Vesugen is a niche adjunct to a real cardiovascular prevention plan, and the plan matters more than the peptide. The plan is lifestyle (aerobic training, resistance training, diet, weight, sleep, stress), evidence-based pharmacology (statins, antihypertensives, antiplatelets, SGLT2 inhibitors, GLP-1 agonists where indicated), preventive screening (lipid panel, blood pressure monitoring, CAC score or carotid imaging in select cases, diabetes screening, kidney function), and clinical relationship (primary care, cardiology when risk is elevated). Vesugen cycling can be layered onto that plan for users who want to experiment with the Khavinson framework. It cannot replace that plan.

IUPAC Name

L-Alanyl-L-glutamyl-L-aspartyl-L-valine

CAS Number

Not yet available

Molecular Formula

Ala-Glu-Asp-Val

Molecular Mass

429.43 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Vesugen Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility